Logo

BioNTech Plans to Initiate the Clinical Study of Malaria and Tuberculosis Vaccines in 2022

Share this

BioNTech Plans to Initiate the Clinical Study of Malaria and Tuberculosis Vaccines in 2022

Shots:

  • BioNTech unveils the plan to develop the first mRNA-based vaccine to prevent malaria with anticipated initiation of the clinical study by the end of 2022
  • The company intends to set up a large vaccine production hub in Africa with the help of local partners and transfer its mRNA technology to Africa. These efforts of the company are supported by WHO and the Africa CDC
  • BioNTech’s Malaria project is part of the ‘eradicateMalaria’ initiative- led by the kENUP Foundation- to hasten the eradication of Malaria. Additionally- the company is planning to start clinical trials for tuberculosis vaccines in 2022- two yrs. after the initiation of the program

  | Ref: GLOBE NEWSWIRE | Image: BioNTech

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions